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Ketorolac is the only nonsteroidal anti-inflammatory
drug currently available in the United States for parenteral
administration. It is supplied and administered as a
racemic mixture that contains a 1:1 ratio of the R(+) and
S(–) stereoisomers. Pharmacologic activity resides almost
exclusively with the S(–) stereoisomer. Analgesic efficacy
of ketorolac has been established in clinical trials in
adults1,2 and published studies in children.3-8 Although
not approved by the Food and Drug Administration for
pediatric use, ketorolac is widely used off-label as a par-
enteral analgesic in children. However, in contrast to the
adult population, there is a paucity of information regard-
ing the pharmacokinetics and metabolism of ketorolac in
children of different ages. Furthermore, there is no previ-
ously published information on the chiral pharmacoki-
netics or metabolism of the drug in children. Conse-
quently, pediatric doses have been derived empirically
through clinical experience with little pharmacokinetic
basis. We studied the racemic and chiral pharmacokinet-
ics and metabolism of ketorolac in a group of children
enrolled in a randomized double-blind comparison of
ketorolac with morphine for postsurgical pain.
METHODS
Patients. Children from 3 to 18 years old with nor-
mal renal and hepatic function who required postsurgi-
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cal analgesia were eligible for enrollment. Patients with
known kidney disease, liver disease, bleeding abnor-
malities, gastrointestinal abnormalities, dehydration,
hypovolemia, heart failure, or aspirin or nonsteroidal
anti-inflammatory drug–induced bronchospasm were
excluded. In addition, patients receiving methotrexate,
thiazide diuretics, b -blocking drugs, or warfarin at the
time of study were excluded. Informed written permis-
sion was obtained from the parent(s) or guardian of
each child before enrollment, and assent was obtained
from children ‡ 7 years old when the child was cogni-
tively competent for age. The study was approved by
the Institutional Review Board of the Children’s Hos-
pital of Michigan.
Dosing. After enrollment, each patient was randomly
assigned to receive a single dose of either morphine or
ketorolac as the first postoperative analgesic after he or
she arrived in the critical care unit. Patients who were
randomized to receive ketorolac were given a single 0.6
mg/kg dose of racemic ketorolac tromethamine infused
intravenously with a syringe pump over a 10-minute
period. Medication was infused through microbore tub-
ing inserted into a port that did not exceed a distance
of 12 inches from the insertion site of the intravenous
canula. The medication infusion was followed by a 5
mL normal saline solution flush.
Pharmacokinetic sampling. Two-milliliter venous
blood samples were drawn into ethylenediaminetetra-
acetic acid tubes from a site contralateral to the infu-
sion site. Samples were obtained before the dose and
at 10, 15, 30, and 60 minutes, hourly from 1 to 6 hours,
and at 8 and 12 hours timed from the beginning of the
infusion. Total blood loss did not exceed 24 mL in any
child and comprised less than 1% of total blood vol-
ume for most children. Plasma was separated and
frozen at –80°C until assay was performed. Urine was
quantitatively collected for 12 to 24 hours after the dose
was administered. Urine was kept on ice at 3°C
throughout the collection to minimize spontaneous
hydrolysis of the glucuronide conjugate. At completion
of the collection the volume was immediately mea-
sured, and an aliquot was frozen and maintained at
–80°C until the assay was performed.
Racemic assays. Racemic ketorolac in plasma and
racemic ketorolac and para-hydroxyketorolac in urine
were measured by HPLC. All assays were performed
in duplicate with a full set of analytical standards.
Authentic racemic ketorolac and para-hydroxyketoro-
lac analytical standards were provided by Syntex
Research (Palo Alto, Calif).
Plasma analytical standards were prepared in blank
plasma over the full range of clinical plasma concen-
trations. One hundred microliters plasma or analytical
standard was diluted with 200 m L sodium acetate
buffer (pH = 6.0) and extracted with 1 mL ethyl acetate
that contained ethylthiobarbituric acid as the internal
standard. The organic phase was separated and dried
under nitrogen. The residue was reconstituted in 100
m L mobile phase and injected onto a Waters C18
MicroBondapak 5 m m reversed-phase column. Mobile
phase was 35% acetonitrile in a 0.05 mol/L sodium
acetate buffer at pH 6.0 with flow rate of 1 to 2
mL/min. Effluent was monitored at 313 nm. The limit
of quantitation was 5 ng/mL, with a linear response
across the full range of concentrations and coefficient
of variation of <10%.
Urine analytical standards that contained authentic
ketorolac and para-hydroxyketorolac were prepared in
fresh blank urine. Chromatographic conditions were
similar to those for plasma, except the mobile phase
was 18% acetonitrile in acetate buffer at pH 6.5 to
accomplish baseline separation of ketorolac and para-
hydroxyketorolac. Chromatographs were obtained for
each set of samples with standard curves for ketorolac
and para-hydroxyketorolac and were analyzed in dupli-
cate. Assays of urine samples were obtained with and
without hydrolysis with b -glucuronidase to estimate
concentration of glucuronidated drug. Bovine b -glu-
curonidase (Sigma Chemical Co, St Louis, Mo) was
reconstituted in 0.05 mol/L acetate buffer (pH = 6.5) at
a concentration of 5000 Fishman units/mL. Aliquots of
each urine sample were diluted 1:10 in either buffer,
b -glucuronidase, or b -glucuronidase plus sacarolactone
(a specific b -glucuronidase inhibitor). Samples were
incubated at 37°C for 12 hours. Preliminary experi-
ments were conducted to establish the conditions that
provided complete stoichiometric hydrolysis of the glu-
curonides. After incubation was performed, samples
were centrifuged and 10 m L supernatant was injected
on column. Concentration of glucuronidated drug was
estimated from the difference in measured concentra-
tion with and without hydrolysis.
Chiral assays. Authentic R(+)- and S(–)-ketorolac
analytical standards were prepared by Chiral Technolo-
gies (Exton, Pa) by preparative chiral HPLC separation
of racemic ketorolac acid. Authenticity and purity of
the respective chiral standards were confirmed by x-ray
crystallography. Standard concentrations of both enan-
tiomers were prepared in plasma and urine, respec-
tively, over the anticipated concentration range.
One hundred microliters of plasma or analytical stan-
dard prepared in plasma was diluted in 200 m L sodium
acetate buffer and extracted into 1.0 mL ethyl acetate
that contained S(+)-6-methoxy a -methyl-2-naphthalene
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acetic acid as the internal standard. The organic phase
was separated and dried under nitrogen, after which the
sample residue was reconstituted in 100 m L mobile
phase and injected on column. R(+)-Ketorolac and S(–)-
ketorolac were quantitatively separated on a Chiracel
OJ-R chiral column (Chiral Technologies). Mobile
phase was 45% acetonitrile in 3 mmol/L perchloric
acid, pH 2.0, with 1.2 mL/min flow. Effluent was mon-
itored at 313 nm. Racemization of ketorolac may occur
during indirect racemic assays that require precolumn
derivatization under strong basic conditions, leading to
spurious results.9 Such conditions were avoided with
the direct chiral separation used in this study.
Urine samples were subjected to chiral assay with
and without b -glucuronidase hydrolysis as described
previously for the racemic assay. Concentration of both
glucuronidated enantiomers was estimated from the dif-
ference in measured concentration with and without
hydrolysis.
The chiral assay provided baseline resolution of the
respective analyte peaks, with R(+)-ketorolac eluting
at 3.0 minutes, S(–)-ketorolac at 3.5 minutes, and the
internal standard at 5.8 minutes. Limit of quantitation
was 5 ng/mL with a coefficient of variation <10%.
Pharmacokinetic analysis. PKAnalyst software
(MicroMath Scientific Software, Salt Lake City, Utah)
was used to estimate plasma pharmacokinetic parame-
ters for each patient from a nonlinear least-squares fit
of plasma concentrations of racemic ketorolac and both
ketorolac enantiomers versus time. Data were fitted to
a biexponential or triexponential model with a 10-
minute zero-order infusion function. Best statistical fit
was determined from the Akaike information criterion.
Data from most of the patients was best fitted with a
biexponential function, although data from several
patients best fitted a triexponential equation. Area under
the concentration versus time curve [AUC(0-12)] was
integrated with the trapezoid method. Total area
[AUC(0-∞)] was calculated by summation of
AUC(0-12) + Cp12/ l n, in which Cp12 is the ketorolac
plasma concentration at 12 hours and l is the terminal
elimination rate constant. Clearance was calculated by
the following: Dose/AUC(0-∞); and apparent volume
of distribution (Vd) was calculated from the equation:
Dose/AUC · l n. Total racemic ketorolac, para-hydroxy-
ketorolac, and ketorolac glucuronide excreted in urine
were determined by multiplying their respective con-
centrations by the total urine collection volume. Total
drug excreted was computed from the sum of the 3
measured components. Fraction of dose recovered in
urine was determined by dividing the quantity of each
compound by the total dose. Analogous values were
computed for both ketorolac enantiomers and their
respective glucuronides. Unfortunately, analytical stan-
dards for the individual para-hydroxyketorolac enan-
tiomers were not available, so they could not be quan-
titated in urine.
Statistical analysis. Pharmacokinetic and metabolic
data were summarized with descriptive statistics. Para-
metric methods for comparison of mean values and cor-
relation statistics were used when appropriate to com-
pare pharmacokinetic and metabolic characteristics of
R(+)- and S(–)-ketorolac. Categorical data were evalu-
ated with appropriate tests for proportions. Null
hypotheses were rejected if a ≤ 0.05.
RESULTS
Demographics. Racemic ketorolac plasma and urine
data were available from 50 children with a median age
of 11.6 years (age range, 3 to 18 years). Patients were
well distributed across the age range, with 11 between
3 to 6 years, 23 between 6 to 12 years, and 16 between
12 to 18 years. Fifty-four percent were female. Plasma
kinetic data on ketorolac enantiomers were obtained
from 47 children with a median age of 11.7 years. Fifty-
five percent were female. Analysis of R(+)- and S(–)-
ketorolac and the respective glucuronides in urine was
possible in 45 children with a median age of 12 years;
49% were female. Sufficient plasma to complete chiral
analysis was not available from 3 children, and suffi-
cient urine was not available from 5 children.
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Figure 1. Comparison of plasma concentrations of R(+)-
and S(–)- ketorolac after 0.6 mg/kg dose of racemic ketoro-
lac administered intravenously over 10-minute period. Area
under the concentration versus time curve of the enantiomers
extrapolated to infinity is significantly different (P < .001).
All points represent mean ± SD; n = 47.
The most common diagnosis (26 of 50) was congen-
ital heart disease in children undergoing elective car-
diac surgical procedures. The next most common diag-
nosis (12 of 50) was scoliosis in children undergoing
corrective spinal surgery. Six children underwent sur-
gical procedures for malignancy and 2 for facial recon-
structive surgery; 4 were coded as “other.”
Urine was collected for 12 hours in 13 children, 16
hours in 2, 17 hours in 2, 18, 19, and 20 hours, respec-
tively, in 1 patient each, 21 hours in 2, 22 hours in 3,
23 hours in 2, and 24 hours in 18. We were concerned
that the variable collection intervals might influence
recovery of drug in the urine. However, the mean per-
centage of dose recovered was not different between
the 12- and 24-hour collections (P = .480), and no cor-
relation was observed between collection interval and
the percentage of dose recovered (Pearson correlation,
0.08; P = .6). Therefore we analyzed all urine data
together regardless of collection interval over the range
of 12 to 24 hours.
Racemic pharmacokinetics. The racemic ketorolac
pharmacokinetic parameter values are summarized in
Table I. These values were well within the range of those
previously reported.10-12 No relationship was observed
between age and Vd and terminal half-life (t1⁄2) or clear-
ance across the age range of children in this study.
We recovered 43.5% ± 13.7% (SD) of the ketorolac
dose in the urine as racemic drug and metabolites
(Table II). Approximately 60% of total ketorolac recov-
ered was parent drug. Ketorolac glucuronide and para-
hydroxyketorolac each comprised approximately 20%
of the remainder.
Chiral-selective pharmacokinetics. Plasma pharmaco-
kinetics of the 2 ketorolac enantiomers differed markedly.
Concentrations of the S(–) enantiomer were lower than
those of the R(+) enantiomer at all time points (Figure 1).
Distribution and terminal elimination t1⁄2 values of the S(–)
enantiomer were shorter, AUC(0-∞) was decreased, and
clearance was significantly greater compared with the
R(+) enantiomer (Table III). The AUC(0-∞) ratio of the
S(–) to R(+) enantiomers was 0.25 ± 0.15.
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Total recovery of R(+)-ketorolac expressed as a per-
centage of dose was 13.8% ± 5.4% compared with
14.3% ± 6.0% for S(–)-ketorolac. This result was not sig-
nificantly different (P = .275). However, a significant dif-
ference was observed in glucuronidation of the 2 enan-
tiomers. S(–)-Ketorolac glucuronide in urine, expressed
as a percentage of dose was, for example, 2.3 times R(+)-
ketorolac glucuronide: 3.6% versus 1.5%. Expressed
another way, S(–)-ketorolac glucuronide comprised 27%
of total S(–)-ketorolac recovered in urine, whereas R(+)-
ketorolac glucuronide comprised only 12% of total R(+)-
ketorolac recovered (Table IV). Unfortunately, we were
unable to evaluate stereoselective para-hydroxylation,
which theoretically also could contribute to differential
metabolism of the 2 enantiomers.
DISCUSSION
The mean t1⁄2 (4.0 hours) and plasma clearance (1.1
mL/min/kg) of racemic ketorolac in the 50 patients in
this study were within the range of those reported pre-
viously. Kerr et al11 studied racemic ketorolac kinetics
in 15 children ranging in age from 1.4 to 17 years and
reported a mean t1⁄2 of 2.7 hours, with a plasma clear-
ance of 0.9 mL/min/kg. Gonzalez-Martin et al10 stud-
ied 14 children from 2 to 8 years old and reported a
mean ketorolac t1⁄2 of 2.3 hours, with a plasma clear-
ance of 1.3 mL/min/kg. Olkkola and Maunuksela12
reported a mean terminal t1⁄2 of 6.1 hours and a mean
plasma clearance of 0.7 mL/min/kg in 10 children who
ranged in age from 4 to 8 years. The longer terminal t1⁄2
reported by Olkkola and Maunuksela12 may be in part
the result of a longer sampling time and may represent
elimination from a deep compartment not detected by
the other studies. They measured plasma concentrations
over a 20-hour period, whereas Kerr et al11 and Gon-
zalez-Martin et al10 sampled for only 6 hours. We sam-
pled for 12 hours, assuming this would represent a min-
imum of 2 t1⁄2 values, based on previously reported t1⁄2
values in young healthy adults.1
With the exception of the study by Olkkola and
Maunuksela,12 the mean t1⁄2 values reported for children
Table II. Urinary recovery of racemic ketorolac (n = 50)
Percent of Percent of total
Drug or metabolite dose drug recovered
Ketorolac 23.4 ± 9.7 57 ± 11.7
para-Hydroxyketorolac 10.5 ± 8.5 22 ± 11.1
Ketorolac glucuronide 10.3 ± 5.9 21 ± 9.8
Total ketorolac 43.5 ± 13.7 100
Data are mean values ± SD.
Table I. Pharmacokinetics of racemic ketorolac (n = 50)
Cmax (ng/mL) 4698 ± 1641
Vd (L/Kg) 0.35 ± 0.2
t1⁄2 a (min) 28.7 ± 20.7
t1⁄2 l (min) 243 ± 137
Plasma CL (mL/min/kg) 1.1 ± 0.5
Data are mean values ± SD.
Cmax, Maximum plasma concentration; Vd, apparent volume of distribution;
t1⁄2 a , distribution half-life; t1⁄2 l , terminal elimination half-life; CL, clearance.
are shorter than the range of mean t1⁄2 values reported
in studies of healthy adults. Reported mean t1⁄2 values
in healthy young adults have ranged from 2.7 to 6.0
hours,1,2 with prevailing values of approximately 5
hours. More striking is the difference in Vd and plasma
clearance between children and adults. The mean Vd in
adults was 0.17 to 0.25 L/kg,1 whereas it was 0.21 to
0.35 L/kg in the pediatric studies. The mean plasma
clearance in studies of adult volunteers1 ranged from
0.3 to 0.55 mL/min/kg, whereas the mean plasma clear-
ance in our 50 subjects was 1.1 mL/min/kg. Clearance
in the other published pediatric studies10-12 ranged from
0.7 to 1.3 mL/min/kg. Because of the greater plasma
clearance in children, larger maintenance doses may be
required than in adults to provide comparable plasma
concentrations.
Recovery of racemic ketorolac in the urine of our sub-
jects was less than that reported by Mroszczak et al13 in
4 adult volunteers. They recovered 90% of the dose in
urine after intravenous administration of 14C-ketorolac.
Of total radioactivity recovered, 56% was unchanged
ketorolac, 11% was para-hydroxyketorolac, and 33% was
polar metabolites, presumably glucuronidated ketorolac.
Although our total recovery was less, the proportional
recovery in our patients was quite similar to that in the
adult study: 57% ketorolac, 22% para-hydroxyketorolac,
and 21% ketorolac glucuronide. Decreased recovery
from the children in our study may be at least partly
attributable to incomplete urine collection from some
children, despite our best efforts to the contrary.
The most impressive observation from this study is
the marked difference between S(–)- and R(+)-ketoro-
lac plasma kinetics, which has not been reported previ-
ously in children. Clearance of the S(–) enantiomer was
4 times that of the R(+) enantiomer. Likewise, the S(–)
enantiomer t1⁄2 was 40% that of the R(+) enantiomer,
and the Vd of the S(–) enantiomer was significantly
greater than that of the R(+) form. Although there are
limited studies of ketorolac chiral kinetics in adults,
similar observations have been reported in a small num-
ber of adult volunteers.9,14,15 The substantially shorter
t1⁄2 of the S(–) enantiomer has important clinical signif-
icance because it is the active stereoisomer.16 Assum-
ing analgesia is related to plasma concentration, previ-
ously reported racemic plasma kinetics may grossly
overestimate the duration of pharmacologic effect.
Several theoretical explanations for the greater clear-
ance of S(–)-ketorolac may be considered. These
include (1) in vivo inversion of S(–)- to R(+)-ketorolac,
(2) stereoselective protein binding, and (3) stereoselec-
tive metabolism.
It is unlikely that in vivo inversion plays a signifi-
cant role because interconversion of S(–)- to R(+)-
ketorolac is negligible in humans. Mroszczak et al15
found that only 6.5% of a dose of S(–)-ketorolac was
converted to the R(+) enantiomer in adult volunteers,
and there was no interconversion of R(+)- to S(–)-
ketorolac.
On the other hand, stereoselective binding of non-
steroidal anti-inflammatory drugs to human serum albu-
min is well documented,17 and ketorolac is no excep-
tion.18 The unbound fraction of S(–)-ketorolac is more
than 2-fold greater than that of R(+)-ketorolac over an
enantiomeric plasma concentration range from 2 to 15
m g/mL. Binding of the 2 enantiomers is not affected by
the presence of the corresponding antipode, although
binding of both is decreased in the presence of octanoic
acid.19 Stereoselective protein binding may signifi-
cantly affect pharmacokinetics of highly bound drugs
with relatively low intrinsic clearance such as ketoro-
lac for which clearance is directly proportional to the
unbound fraction. Although binding differences have a
modest affect on Vd, the effect on clearance is substan-
tially greater. Correspondingly, the terminal elimina-
tion t1⁄2 is shortened in the presence of decreased bind-
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Table III. Pharmacokinetics of ketorolac enantiomers
(n = 47)
Pharmacokinetic
parameter S(–)-Ketorolac R(+)-Ketorolac
Cmax (ng/mL) 1609 ± 751 2845 ± 1007*
Vd (L/Kg) 0.82 ± 0.38 0.50 ± 0.34*
t1⁄2 a (min) 17 ± 21 32 ± 29†
t1⁄2 l (min) 107 ± 59 259 ± 131*
AUC(0-∞) (m g · min/mL) 126 ± 63 508 ± 208*
Plasma CL (mL/min/kg) 6.2 ± 3.3 1.4 ± 0.5*
Data are mean values ± SD.
Cmax, Maximum plasma concentration; Vd, apparent volume of distribution;
t1⁄2 a , distribution half-life; t1⁄2 l , terminal elimination half-life; AUC(0-∞), area
under the concentration–time curve extrapolated to infinity; CL, clearance.
*P < .001.
†P < .007.
Table IV. Urinary recovery of ketorolac enantiomers
(n = 45)
Percent Percent of total
Drug or metabolite of dose enantiomer recovered
R(+)-Ketorolac 12.3 ± 5.1 88 ± 9
S(–)-Ketorolac 10.7 ± 5.0 73 ± 13
R(+)-Glucuronide 1.5 ± 1.2* 12 ± 7*
S(–)-Glucuronide 3.6 ± 2.3* 27 ± 15*
Data are mean values ± SD.
*Difference between R(+) and S(–) significant, P < .001.
ing because t1⁄2 is equal to the ratio of Vd to total body
clearance. The shorter distribution t1⁄2 of S(–)-ketorolac
observed in this study is also consistent with decreased
protein binding. The differences in S(–)- and R(+)-
ketorolac plasma kinetics in our study can be explained
by stereoselective protein binding, although chiral-
selective metabolism cannot be excluded.
None of the previously published studies in adults
or children has explored enantiomer-specific recovery
of ketorolac metabolites in the urine. Although the data
in our study are incomplete because of the unavailabil-
ity of analytical standards for S(–)- and R(+)-para-
hydroxyketorolac, we did observe a significant differ-
ence in glucuronidation of the 2 enantiomers. The
amount of S(–)-ketorolac glucuronide in urine was 2.3
times that of the R(+) isomer. This result is consistent
with stereoselective conjugation, which could con-
tribute to greater clearance of S(–)-ketorolac. In the-
ory, both the acid and para-hydroxyglucuronides may
be formed. We were unable to distinguish the 2 glu-
curonides and therefore cannot rule out preferential
glucuronidation of S(–)-para-hydroxyketorolac and
S(–)-ketorolac. Conclusions regarding selective para-
hydroxylation cannot be drawn from our study, and
there is no other available information regarding stereo-
selective hydroxylation.
In conclusion, clearance of racemic ketorolac in chil-
dren is approximately double the clearance of the drug
in adults. This finding suggests that weight-adjusted
maintenance doses may have to be greater in children
to achieve comparable plasma concentrations. Although
the t1⁄2 of racemic ketorolac tends to be shorter in chil-
dren, there is considerable overlap with t1⁄2 values
reported in adults, and the difference is not of a mag-
nitude to require a decrease in the recommended dos-
ing interval. Almost 60% of ketorolac recovered in the
urine is parent drug, with para-hydroxyketorolac and
ketorolac glucuronide comprising approximately 20%
each. This result implies that ketorolac clearance will
be decreased in the presence of kidney failure.
Clearance of S(–)-ketorolac is approximately 4 times
the clearance of R(+)-ketorolac, resulting in much
lower concentrations of the pharmacologically active
S(–) enantiomer. The t1⁄2 of the S(–) isomer is also
shorter. This may have clinical implications because
the t1⁄2 of racemic ketorolac may grossly overestimate
the duration of pharmacologic effect. Enantiomeric
pharmacokinetic differences are best explained by
stereoselective plasma protein binding. However,
greater glucuronidation of the S(–) enantiomer sug-
gests that stereoselective metabolism may also be a
contributing factor.
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